Loading
A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Daiichi Sankyo, now recruiting.
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT04145622 by Daiichi Sankyo, with 250 participants planned, started 2019-11-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Ifinatamab deruxtecan (I-DXd).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/